Gapping up
In reaction to strong earnings/guidance:
- ATHN +9.3%, OPK +8.1%, ATHM +3.4%, ACB +3.2%
M&A news:
- APTI +51.5% (to be acquired by an affiliate of Vista Equity Partners for $38.00/share in cash)
- CCRC +34.4% (receives non-binding 'Going Private' proposal for $16.00 per share)
- ISCA +6% (NASCAR makes non-binding offer to acquire ISCA for $42/share)
Other news:
- EIDX +12.9% (reports positive Phase 2 Data for AG10)
- LCI +10.1% (enters into agreement with Amneal Pharmaceuticals for Levothyroxine)
- FATE +5.9% (clinical data of FATE-NK100 and provides regulatory update on landmark IND application for FT500)
- NKTR +4.9% (presents new efficacy, safety and biomarker data its Immuno-Oncology pipeline)
- ZIOP +2.4% (enters securities purchase agreements for the sale of its common stock and warrants to purchase common stock in a private placement that is expected to result in gross proceeds to the Company of ~ $50 million)
- ESPR +1.9% (presentation of Final Study 3 results)
- CRVS +1.8% (updated results from CPI-444 and CPI-006 )
- ZFGN +1.1% (entered into $50 mln at-the-market offering sales agreement with Cowen) .
Analyst comments:
- CROX +8.4% (upgraded to Neutral from Negative at Susquehanna)
- LB +2.9% (upgraded to Outperform from Market Perform at Wells Fargo)
- AAL +1.3% (initiated with a Buy at Goldman)
![]()